Title
The Kidney Failure Risk Equation for Prediction of Allograft Loss in Kidney Transplant Recipients.

Permalink
https://escholarship.org/uc/item/8fx5h1hm

Journal
Kidney medicine, 2(6)

ISSN
2590-0595

Authors
Chu, Chi D
Ku, Elaine
Fallahzadeh, Mohammad Kazem
et al.

Publication Date
2020-11-01

DOI
10.1016/j.xkme.2020.09.004

Peer reviewed
The Kidney Failure Risk Equation for Prediction of Allograft Loss in Kidney Transplant Recipients

Chi D. Chu, Elaine Ku, Mohammad Kazem Fallahzadeh, Charles E. McCulloch, and Delphine S. Tuot

Rationale & Objective: The Kidney Failure Risk Equation (KFRE) is a simple widely validated prediction model using age, sex, estimated glomerular filtration rate, and urinary albumin-creatinine ratio to predict the risk for end-stage kidney disease. Data are limited for its applicability to kidney transplant recipients.

Study Design: Validation study of the KFRE as a post hoc analysis of the Folic Acid for Vascular Outcomes Reduction in Transplantation (FAVORIT) Trial.

Setting & Participants: Adult kidney transplant recipients with functioning kidney allografts at least 6 months posttransplantation from 30 centers in the United States, Canada, and Brazil. Participants with estimated glomerular filtration rates < 60 mL/min/1.73 m² at study entry were included.

Predictor: 2- and 5-year kidney failure risk predicted by the KFRE using variables at study entry.

Outcome: Graft loss, defined by initiation of dialysis.

Analytical Approach: Discrimination of the KFRE was assessed using C statistics; calibration was assessed by plotting predicted risk against observed cumulative incidence of graft loss.

Results: 2,889 participants were included. Within 2 years, 98 participants developed graft loss, 107 participants died with a functioning graft, and 129 participants were lost to follow-up, and by 5 years, 252 had developed graft loss, 265 died with a functioning graft, and 1,543 were lost to follow-up. The KFRE demonstrated accurate calibration and discrimination (C statistic, 0.85 [95% CI, 0.81-0.88] at 2 years and 0.81 [95% CI, 0.78-0.84] at 5 years); performance was similar regardless of donor type (living vs deceased) and graft vintage, with the noted exception of poorer calibration for graft vintage less than 2 years.

Limitations: Unavailable cause of graft loss.

Conclusions: The KFRE accurately predicted the risk for graft loss among adult kidney transplant recipients with graft vintage longer than 2 years and may be a useful prognostic tool for nephrologists caring for kidney transplant recipients.

METHODS
We studied participants enrolled in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Details of the study design have previously been described. In brief, the FAVORIT study was a multicenter randomized controlled trial designed to study the effect of folic acid, vitamin B₆, and vitamin B₁₂...
supplementation on cardiovascular outcomes in kidney transplant recipients with elevated total homocysteine levels. Participants were randomly assigned to either a multivitamin containing a high-dose combination of folate acid, vitamin B₆, and vitamin B₁₂ or a multivitamin containing no folate acid and low doses of vitamin B₆ and B₁₂ based on estimated average requirement values. A total of 4,110 participants were enrolled from 30 clinical sites (27 in the United States, 2 in Canada, and 1 in Brazil) from 2002 through 2007, and follow-up ended in 2009.

The study protocol was approved by the institutional review board at each site, and written informed consent was obtained from all participants. Because the FAVORIT trial did not show statistically significant differences in either all-cause mortality or graft loss, we treated the trial as a cohort study for all analyses.¹⁹

Study Population
FAVORIT recruited prevalent kidney transplant recipients aged 35 to 75 years who had a functional allograft for at least 6 months. To be eligible, participants had to have stable kidney function, defined initially as estimated creatinine clearance ≥ 30 mL/min but redefined in 2005 as ≥30 mL/min in men and ≥25 mL/min in women. An elevated serum homocysteine level was also required (≥12 μmol/L for men and ≥11 μmol/L for women) for inclusion.

For our study, we excluded participants with eGFRs ≥ 60 mL/min/1.73 m² at the baseline study visit because the KFRE was derived and validated among persons with eGFRs below this level. We also excluded participants with missing baseline UACRs (n = 290) or missing eGFRs (n = 51), which are required for the KFRE. Although urinary protein excretion has sometimes been substituted in the KFRE for validation studies when urinary albumin excretion was unavailable, urinary protein testing was not performed in the study protocol and therefore could not be used when UACR was missing.³ Because urinary albumin and creatinine testing were performed during the baseline but not during follow-up study visits, participants could not be incorporated into the cohort if eGFR decreased to <60 mL/min/1.73 m² at a later study visit.

Variables
Demographic and clinical characteristics were collected for participants during their baseline study visit, which defined the start of follow-up time for each participant. The CKD Epidemiology Collaboration (CKD-EPI) equation was used to calculate eGFR.²⁰ Laboratory methods for measuring serum creatinine, urinary creatinine, and urinary albumin have been previously described.²¹ Using the eGFR and UACR from the baseline visit, the 2- and 5-year risks for end-stage kidney disease for each participant were calculated using the 4-variable KFRE (item S1). The North American KFRE equation was used for participants in the United States and Canada; the non–North American KFRE equation was used for those in Brazil. The KFRE-predicted risk for end-stage kidney disease served as the primary predictor.

Outcomes
Participants were followed up every 6 months by alternating telephone interviews and clinic visits to obtain study outcomes, including ascertainment of death and dialysis initiation. Outcome ascertainment was supplemented by review of administrative and medical records as necessary. The primary outcome for this study was graft loss, defined by initiation of maintenance dialysis. Data for pre-emptive retransplantation were not available in the FAVORIT study data, and pre-emptive transplantation was not classified as graft loss according to the study protocol. Follow-up for outcome ascertainment ended on death, loss to follow-up, or administrative censoring at trial conclusion on June 24, 2009. The occurrence of a nonfatal cardiovascular event (ie, a primary outcome of FAVORIT) was not treated as a censoring event.

Statistical Analysis
Predictive performance of the KFRE was assessed using metrics for discrimination and calibration. Following the usual recommendations for prediction model validation in survival analysis,²² we used the entire follow-up period to assess discrimination and calibration at 2 and 5 years. We assessed discrimination by computing C statistics with 95% CIs determined using a bootstrap approach with 500 repetitions.¹¹ The 2- and 5-year C statistics represent the proportion of all pairs of participants, at least 1 of whom developed graft loss within 2 or 5 years, respectively, for which the KFRE assigned a higher risk to the participant who developed graft loss earlier. To account for the competing risk for death, we used an approach described by Wolbers et al²⁴ for computing C statistics in the presence of competing events based on the Fine and Gray
model. In this approach, participants are not censored at the occurrence of a competing event but instead are retained in the risk set beyond the end of the maximum observed follow-up time.

Calibration was assessed graphically by plotting observed risk for graft loss versus mean KFRE-predicted risk within previously proposed categories of predicted risk: 0% to <2%, 2% to <6%, 6% to <10%, 10% to <20%, and ≥20% for 2-year risk; and 0% to <3%, 3% to <5%, 5% to <10%, 10% to <25%, 25% to <50%, and ≥50% for 5-year risk. Observed risk for graft loss was obtained by estimating the cause-specific cumulative incidence of graft loss at 2 and 5 years, with death treated as a competing risk. Although treatment of death as a competing event did not result in significant differences in the initial derivation of the KFRE, we treated death as a competing event in our primary analysis because the cumulative incidence obtained in this manner has been proposed to have a more suitable interpretation for clinical risk prediction.

We assessed discrimination and calibration in the overall cohort and in prespecified subgroups based on donor type (living vs deceased) and graft vintage (categorized as <2, 2-<5, and ≥5 years since transplantation). Donor type may affect predictive performance given that living donor allografts have consistently shown longer graft survival compared with deceased donor allografts. We chose to examine subgroups based on vintage because differences in the risk and causes of graft failure in earlier versus later posttransplantation periods could affect predictive performance of the KFRE. Specifically, because early graft failure is often related to rejection, the KFRE, which does not include immunologic data, may not be as predictive. In addition, evidence for accurate prediction at longer graft vintage is important because most prediction models for graft failure have been validated in the early posttransplantation period and have not been validated in later posttransplantation periods, with the exception of the iBox model of Loupy et al.

Study data were obtained from the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository in deidentified form. The University of California, San Francisco Institutional Review Board considers this study exempt human subjects research. We followed guidelines for reporting validation of a risk prediction model as described by the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) Statement (Item S2). All analyses were performed using R, version 3.6.1 (R Foundation for Statistical Computing), and Stata/IC, version 15.1 (StataCorp).

**Sensitivity Analyses**

As sensitivity analysis, we assessed discrimination and calibration treating death as a censoring rather than a competing event, as in the original derivation of the KFRE, using Cox proportional hazards models. In an additional sensitivity analysis, we performed analyses in which we included the 880 participants with eGFRs ≥ 60 mL/min/1.73 m², truncating these values to 60 for calculation of the KFRE.

**RESULTS**

Of the 4,110 participants in FAVORIT, a total of 1,221 were excluded due to missing baseline data or eGFR ≥ 60 mL/min/1.73 m² (Fig 1). Baseline characteristics for 2,889 included participants are shown in Table 1. Mean age was 52.2 (standard deviation [SD], 9.3) years. Mean eGFR was 41 (SD, 11) mL/min/1.73 m² and median UACR was 28 (interquartile range [IQR], 10-119) mg/g. A total of 43% of participants (n = 1,229) received kidney transplants from a living donor and 57% (n = 1,633) had deceased donor transplants. Median graft vintage was 4.3 (IQR, 1.7-8.0) years; the distribution is shown in Figure S1.

Median follow-up time was 3.6 (IQR, 2.9-5.2) years. By 2 years of follow-up, 98 participants had experienced graft loss and 107 had died with a functioning graft. There were 129 participants (4.5% of the total study population) who were lost to follow-up or administratively censored before 2 years. By 5 years, 252 participants had experienced graft loss, 265 had died with a functioning graft, and 1,543 were lost to follow-up or administratively censored. Full distributions of KFRE-predicted risk by graft loss status are shown in Figure S2.
In the overall cohort, there was generally close agreement between predicted and observed risk for graft loss at 2 years (Fig 2) but with overestimation of risk in the highest risk categories. The KFRE was well calibrated for both deceased donor and living donor grafts. Calibration was poorer for the subgroup with graft vintage less than 2 years, largely due to overestimation of predicted risk across multiple risk categories. The KFRE was relatively well calibrated in subgroups of graft vintage of 2 to less than 5 years and 5 years or greater. Calibration plots for 5-year predictions (Fig 3) showed overall adequate agreement between observed and predicted risk, but with a pattern of underestimation of risk in lower risk categories and overestimation of risk in the highest risk category. Overestimation of risk was particularly severe in subgroups of graft vintage less than 2 years and living donor grafts, for which mean predicted risk (75.9% and 70.1%, respectively) was nearly double the observed graft loss risk (42.7% and 41.0%, respectively).

In sensitivity analyses treating death as censoring, C statistics showed that minimally different discrimination and calibration was also similar, though overestimation of risk in the highest risk categories was slightly attenuated (Figs S3 and S4). In sensitivity analyses in which participants with eGFRs ≥ 45 mL/min/1.73 m² were included, discrimination and calibration performances were not materially changed (Figs S5 and S6).

**DISCUSSION**

In this study, we found that the KFRE demonstrated accurate predictive performance in estimating the risk for graft loss at 2 years for kidney transplant recipients with eGFRs < 60 mL/min/1.73 m², with the noted exception of poor calibration for participants less than 2 years posttransplantation. The KFRE has been evaluated for kidney transplantation in 2 prior studies, examining 956 kidney transplant recipients from a single center in Canada (Akbari et al) and examining 3,659 patients from 4 US and Canadian centers (Tangri et al). Both prior studies showed good to excellent discrimination with better discrimination for 2-year predictions compared with 5-year predictions, findings fairly comparable to our study. Akbari et al reported C statistics (assessed at varying time points posttransplantation) ranging from 0.73 to 0.93 for the 2-year KFRE and from 0.72 to 0.77 for the 5-year KFRE. In Tangri et al, C statistics were 0.81 and 0.73 for the 2- and 5-year KFREs, respectively, but in a subgroup of patients with eGFRs < 45 mL/min/1.73 m², discrimination was higher (0.88 and 0.83, respectively). Notably, more than half (60.7%) of our study population had eGFRs < 45 mL/min/1.73 m², and our C statistics of 0.85 and 0.81 at 2 and 5 years, respectively, are more comparable to this low eGFR subgroup.

Given that eGFR and albuminuria are independently powerful predictors of graft failure, the ability of the KFRE to predict accurately was unsurprising. However, our

---

**Table 1. Validation Cohort Baseline Characteristics**

| Characteristic               | Parameter Estimate |
|------------------------------|--------------------|
| Age, y                       | 52.2 (9.3)         |
| Female sex                   | 1,127 (39.0%)      |
| Race                         |                    |
| American Indian or Alaska Native | 24 (0.8%) |
| Asian                        | 59 (2.1%)          |
| Black                        | 456 (15.9%)        |
| Mixed                        | 100 (3.5%)         |
| Native Hawaiian or Pacific Islander | 4 (0.1%) |
| White                        | 2,226 (77.6%)      |
| Hispanic ethnicity           | 515 (17.9%)        |
| Graft type                   |                    |
| Living donor                 | 1,229 (42.9%)      |
| Deceased donor               | 1,635 (57.1%)      |
| Graft vintage, y             | 4.3 [1.7-8.0]      |
| Country                      |                    |
| United States                | 2,071 (71.7%)      |
| Canada                       | 378 (13.1%)        |
| Brazil                       | 440 (15.2%)        |
| Hypertension                 | 2,680 (92.8%)      |
| Diabetes                     | 1,145 (39.7%)      |
| Prior myocardial infarction  | 407 (14.1%)        |
| Prior stroke                 | 198 (6.9%)         |
| Pancreatic transplant        | 220 (7.6%)         |
| eGFR by CKD-EPI, mL/min/1.73 m² | 41 (11)          |
| eGFR range, mL/min/1.73 m²   |                    |
| 45-<60                       | 1,135 (39.3%)      |
| 30-<45                       | 1,273 (44.1%)      |
| <30                          | 481 (16.6%)        |
| UACR, mg/g                   | 28 [10-119]        |
| Immunosuppression regimen    |                    |
| Prednisone, ciclosporine, MMF| 797 (27.6%)        |
| Prednisone, tacrolimus, MMF  | 667 (23.1%)        |
| Prednisone, ciclosporine, azathioprine | 295 (10.2%) |
| Prednisone, ciclosporine     | 234 (8.1%)         |
| Prednisone, MMF              | 137 (4.7%)         |
| Prednisone, tacrolimus       | 120 (4.2%)         |
| Other (including prednisone) | 395 (13.7%)        |
| Other (prednisone-sparing)   | 244 (8.4%)         |

Note: N = 2,889. Values expressed as mean (standard deviation), number (percent), or median [interquartile range]. Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; UACR, urinary albumin-creatinine ratio.

---

As shown in Table 2, the KFRE provided high discrimination at 2 years in the overall cohort (C statistic, 0.85; 95% CI, 0.81-0.88) and in subgroups of donor graft type and graft vintage, with C statistics ranging from 0.83 to 0.85. Discrimination for 5-year prediction was less (overall C statistic, 0.81; 95% CI, 0.78-0.84) but across subgroups still remained in a useful range from 0.78 to 0.82.

In the overall cohort, there was generally close agreement between predicted and observed risk for graft loss at 2 years (Fig 2) but with overestimation of risk in the highest risk category. Participants in the lowest predicted risk category (<2% predicted risk) had an observed risk for graft loss of 0.9% (95% CI, 0.6%-1.5%), whereas those in the highest predicted risk category had a mean predicted risk of 35.2% as compared with an observed risk for graft loss of 28.9% (95% CI, 19.9%-38.5%).

In subgroup analyses, the KFRE was well calibrated for both deceased donor and living donor grafts. Calibration was poorer for the subgroup with graft vintage less than 2 years, largely due to overestimation of predicted risk across multiple risk categories. The KFRE was relatively well calibrated in subgroups of graft vintage of 2 to less than 5 years and 5 years or greater. Calibration plots for 5-year predictions (Fig 3) showed overall adequate agreement between observed and predicted risk, but with a pattern of underestimation of risk in lower risk categories and overestimation of risk in the highest risk category. Overestimation of risk was particularly severe in subgroups of graft vintage less than 2 years and living donor grafts, for which mean predicted risk (75.9% and 70.1%, respectively) was nearly double the observed graft loss risk (42.7% and 41.0%, respectively).
results highlight important limitations of the KFRE in the transplant setting. Although discrimination was in a clinically useful range overall for both 2- and 5-year predictions, the KFRE was not well calibrated for predictions in the setting of graft vintage less than 2 years. This is consistent with the findings of between-cohort variability in calibration in Tangri et al., 17 in which prediction was assessed at the 1-year posttransplantation time point. In addition, we found that 5-year predictions tended to underestimate risk when risk is low and overestimate risk when risk is high, the latter being potentially severely discordant. Thus, unless risk is very low, the clinical usefulness of the KFRE is limited for counseling patients regarding long-term likelihood of graft loss, even when discrimination is acceptable.

Because numerous models have been developed for predicting graft loss in kidney transplant recipients, a key consideration for assessing the clinical applicability of prognostic models is the time of risk assessment, or the prognostic time origin, relative to the date of transplantation. This is the time point from which outcomes are defined (eg, 2-year risk or 5-year risk) and it is also the time point near which predictors (eg, eGFR and UACR) are typically ascertained. A systematic review of published risk prediction models for kidney allograft failure found that most models used predictors ascertained at or shortly after the time of transplantation (typically within 6-12 months posttransplantation). 15

For instance, the Birmingham risk model, which uses recipient age, sex, ethnicity, eGFR, UACR, and prior acute rejection at 1-year posttransplantation, has demonstrated good to excellent discrimination (C statistics, 0.78-0.90 in validation cohorts) and good calibration for predicting 5-year risk for death-censored graft loss. 13 This model has been subsequently refined with the addition of donor-specific alloantibody status and histologic data (presence of glomerulitis or chronic interstitial fibrosis), with further improvement in prediction. 14

By contrast, few prediction models for graft loss have been validated that use any time point after transplantation as the prognostic time origin. 17 Such models would be applicable for kidney transplant recipients who may be several years out from the date of transplantation and are often primarily monitored by general nephrologists in the community. In the setting of routine follow-up, similar to long-term monitoring of nontransplantation CKD, the ability to obtain updateable predictions for kidney failure within some time frame (eg, 2 years) after each visit would be well suited for advising patients and informing clinical decision making in real time. In the present study, the KFRE provided accurate predictions for kidney transplant recipients over a wide range of time points years after transplantation.

Given that most transplant centers refer kidney transplant recipients back to general nephrologists for comanagement within 12 months of transplantation, the KFRE may be advantageous in several ways. 35 First, it is a simple prognostic model that general nephrologists may already be familiar with for assessing prognosis in nontransplantation patients with CKD. Second, the KFRE uses data routinely collected in nephrology care, and nephrologists in the community are likely to have up-to-date values readily available in local health records. Third, the simplicity of the KFRE makes it particularly amenable to automated reporting in electronic health records, and if implemented in this manner, it may alert clinicians to high-risk patients when there has not been a recent biopsy or DSA testing.

However, the KFRE should not replace more complex prognostic models that have been validated for kidney transplant recipients. For kidney transplant recipients who are within 1 year posttransplantation, it may be more appropriate to apply more detailed prognostic models that incorporate histologic and immunologic prognostic factors and that have demonstrated excellent performance in the early posttransplantation setting. 13, 14 For patients who are many years posttransplantation, the iBox model can be used if donor-specific antibody testing and biopsy data are available. 17

Another limitation of the KFRE is that when eGFR is >60 mL/min/1.73 m², predicted risk estimates are invariably low and thus add little to meaningful risk stratification necessary to inform clinical decisions. In this setting, prognostic models that incorporate additional

Table 2. C Statistics for 4-Variable KFRE Applied to Kidney Transplant Recipients in the FAVORIT Cohort

| Population | n  | 2-y Outcomes | C Statistic (95% CI) | 5-y Outcomes | C Statistic (95% CI) |
|------------|----|--------------|---------------------|--------------|---------------------|
|            |    | Graft Loss Events |                     | Graft Loss Events |                     |
| Overall    | 2,889 | 98 | 0.85 (0.81-0.88) | 252 | 0.81 (0.78-0.84) |
| Donor type |    |              |                     |              |                     |
| Deceased   | 1,633 | 65 | 0.85 (0.81-0.89) | 165 | 0.81 (0.78-0.84) |
| Living     | 1,229 | 30 | 0.83 (0.75-0.92) | 82  | 0.80 (0.75-0.84) |
| Graft vintage |      |              |                     |              |                     |
| <2 y       | 818  | 21 | 0.83 (0.77-0.90) | 49  | 0.78 (0.72-0.84) |
| 2–5 y      | 768  | 21 | 0.83 (0.74-0.94) | 64  | 0.80 (0.75-0.85) |
| ≥5 y       | 1,285 | 54 | 0.85 (0.81-0.90) | 135 | 0.82 (0.78-0.85) |

Note: Subgroup counts do not sum to 2,889 due to missing data for donor type (n = 27) and graft vintage (n = 18).

Abbreviations: FAVORIT, Folic Acid for Vascular Outcome Reduction in Transplantation study; KFRE, Kidney Failure Risk Equation.
transplant-specific predictors beyond age, sex, eGFR, and UACR and that were developed and validated without eGFR restriction may be more appropriate for risk stratification.\textsuperscript{13,17}

Strengths of our study included the use of a relatively large multicenter validation cohort consisting of individuals with a wide range of graft vintages. This increased the applicability of our results because prediction of allograft failure did not require measurement of variables at a specific time posttransplantation. Also, there was little loss to follow-up for outcomes at 2 years. The rigorous use of analytical techniques to account for the

\textbf{Figure 2.} Observed versus predicted graft loss risk using 4-variable Kidney Failure Risk Equation at 2 years. The dotted line denotes perfect agreement between observed and predicted risk. Error bars represent 95\% CIs for cumulative incidence of graft loss with return to dialysis within 2 years. (B) Error bars are not shown for the 6\% to <10\% predicted risk category because 0 of the 34 corresponding participants had experienced graft loss by the 2-year time point.

transplant-specific predictors beyond age, sex, eGFR, and UACR and that were developed and validated without eGFR restriction may be more appropriate for risk stratification.\textsuperscript{13,17}

Strengths of our study included the use of a relatively large multicenter validation cohort consisting of individuals with a wide range of graft vintages. This increased the applicability of our results because prediction of allograft failure did not require measurement of variables at a specific time posttransplantation. Also, there was little loss to follow-up for outcomes at 2 years. The rigorous use of analytical techniques to account for the
competing risk for death when estimating C statistics and risks for graft loss was another strength. Because death with a functioning graft occurred with greater incidence than graft loss in our cohort, accounting for death as a competing event avoided bias due to censoring death, which would lead to overestimation of the absolute risk for dialysis.\textsuperscript{15,36}

Our study had several limitations. First, no data were available for the reason for graft loss. The 5-year results should be interpreted with caution due to significant loss to follow-up. Another limitation was a relatively low crude rate of graft loss events within 2 years (98 of 2,889 [3.4%]). This may have been because FAVORIT enrolled participants with stable kidney function, many
having been stable for several years posttransplantation. With such low rates of allograft loss within 2 years, high
discrimination or calibration does not necessarily translate into clinically useful prognosis for patients beyond a
reassurance that risk for graft failure is very low. However, this does not necessarily preclude the usefulness of
risk prediction for other applications in which high discrimination is valuable, such as allocation of limited
resources to those with highest risk, identification of high-risk individuals to optimize power in clinical trial
enrollment, or surrogate end point development. FAVORIT eligibility criteria required participants to have
elevated baseline serum homocysteine levels so it is un-
known whether our results would apply to individuals
without elevated homocysteine levels. In particular, ho-
mcysteine levels ≥ 12 μmol/L have been associated with
increased risk for both graft loss and mortality in the
kidney transplant population. This suggests that if the
KFRE is accurate for kidney transplant recipients with
elevated homocysteine levels, it may overestimate risk for
those without elevated homocysteine levels. However,
this selection criterion should not preclude generaliz-
ability of the result to most of the kidney transplant
recipient population, which has been shown to have
elevated homocysteine levels compared with the general
population. Consistent with this, most (68%) of
those who underwent eligibility screening for FAVORIT
met the homocysteine level criterion for study entry.

In conclusion, the KFRE provided accurate prediction
for the risk for graft loss among prevalent adult kidney
transplant recipients with eGFRs < 60 mL/min/1.73 m²
who are at least 2 years posttransplantation in a multicenter
multinational setting. The KFRE is a simple and parsimo-
nous tool for nephrologists to assess prognosis and aid
decision making in routine follow-up of kidney transplant
recipients many years after transplantation. Further studies
are needed to assess the utility of the KFRE and whether its
routine application to guide care for kidney transplant
recipients approaching the end of their allograft life yields
meaningful clinical benefits.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Figure S1: Histogram of Graft Vintage at Cohort Baseline

Figure S2: Distribution of KFRE-Predicted Graft Loss Risk by Graft Loss Outcome

Figure S3: Death-Censored Graft Loss Versus Predicted Graft Loss Risk Using 4-Variable KFRE at 2 Years

Figure S4: Death-Censored Graft Loss Versus Predicted Graft Loss Risk Using 4-Variable KFRE at 5 Years

Figure S5: Observed Versus Predicted Graft Loss Risk Using 4-Variable KFRE at 2 Years; eGFR Truncated Above 60 ml/min/1.73m²

Figure S6: Observed Versus Predicted Graft Loss Risk Using 4-Variable KFRE at 5 Years; eGFR Truncated Above 60 ml/min/1.73m²

REFERENCES

1. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559.
2. Tangri N, Grams ME, Levey AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164-174.
3. Winnicki E, McCulloch CE, Mitanes MM, Furth SL, Warady BA, Ku E. Use of the Kidney Failure Risk Equation to determine the risk of progression to end-stage renal disease in children with chronic kidney disease. JAMA Pediatr. 2018;172(2):174-180.
4. Major RW, Shepherd D, Medcalf JF, Xu G, Gray LJ, Brunskill NJ. The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: an external
validation and clinical impact projection cohort study. *PLOS Med.* 2019;16(11):e1002955.

5. Wang Y, Nguyen FNHL, Allen JC, Lew JQJ, Tan NC, Jafar TH. Validation of the Kidney Failure Risk Equation for end-stage kidney disease in Southeast Asia. *BMC Nephrol.* 2019;20(1):451.

6. Peeters MJ, van Zuilen AD, van den Brand JAOG, et al. Validation of the Kidney Failure Risk Equation in European CKD patients. *Nephrol Dial Transplant.* 2013;28(7):1773-1779.

7. Hingwala J, Wojciechowski P, Hiebert B, et al. Risk-based triage for nephrology referrals using the Kidney Failure Risk Equation. *Can J Kidney Health Dis.* 2017;4 https://doi.org/10.1177/2054358117722782.

8. Tangri N, Ferguson T, Komenda P, Pro: risk scores for chronic kidney disease progression are robust, powerful and ready for implementation. *Nephrol Dial Transplant.* 2017;32(6):748-751.

9. Smekal MD, Tam-Tham H, Finlay J, et al. Patient and provider experience and perspectives of a risk-based approach to multidisciplinary chronic kidney disease care: a mixed methods study. *BMC Nephrol.* 2019;20:110.

10. Smekal MD, Tam-Tham H, Finlay J, et al. Perceived benefits and challenges of a risk-based approach to multidisciplinary chronic kidney disease care: a qualitative descriptive study. *Can J Kidney Health Dis.* 2018;5 https://doi.org/10.1177/2054358118763809.

11. Kasiske BL, Israni AK, Snyder JJ, Skeans MA, Peng Y, Weinhandl ED. A simple tool to predict outcomes after kidney transplant. *Am J Kidney Dis.* 2010;56(5):947-960.

12. Moore J, He X, Shabir S, et al. Development and evaluation of a composite risk score to predict kidney transplant failure. *Am J Kidney Dis.* 2011;57(5):744-751.

13. Shabir S, Halimi J-M, Cherukuri A, et al. Predicting 5-year risk of kidney transplant failure: a prediction instrument using data available at 1 year posttransplantation. *Am J Kidney Dis.* 2014;63(4):643-651.

14. Gonzales MM, Bentall A, Kremers WK, Steggall MD, Borrows R. Predicting individual renal allograft outcomes using risk models with 1-year surveillance biopsy and alloantibody data. *J Am Soc Nephrol.* 2016;27(10):3165-3174.

15. Kaboré R, Haller MC, Harambat J, Heinze G, Leffondré K. Risk prediction models for graft failure in kidney transplantation: a systematic review. *Nephrol Dial Transplant.* 2017;32(suppl_2):ii68-ii76.

16. Akbari S, Knoll G, White CA, Kumar T, Fairhead T, Akbari A. Accuracy of Kidney Failure Risk Equation in transplant recipients. *Kidney Int Rep.* 2019;4(9):1334-1337.

17. Loupy A, Aubert O, Orandi BJ, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. *BMJ.* 2019;366:i4923.

18. Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. *Am Heart J.* 2006;152(3):448 e1-2.

19. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. *Circulation.* 2011;123(16):1763-1770.

20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604-612.

21. Bostom AG, Carpenter MA, Hunsicker L, et al. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. *Am J Kidney Dis.* 2009;53(1):121-128.

22. Royo J, Altman DG. External validation of a Cox prognostic model: principles and methods. *BMC Med Res Methodol.* 2013;13(1):33.

23. Newson R. Comparing the predictive powers of survival models using Harrell's C or Somers' D. *Stat J.* 2010;30:339-358.

24. Wolbers M, Koller MT, Witteman JCM, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiology.* 2009;20(4):555-561.

25. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc.* 1999;94:496-509.

26. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med.* 2007;26(11):2389-2430.

27. Holme I, Fellström BC, Jardine AG, Hartmann A, Holdaas H. Model comparisons of competing risk and recurrent events for graft failure in renal transplant recipients. *Clin J Am Soc Nephrol.* 2013;8(2):241-247.

28. Ravani P, Fiocco M, Liu P, et al. Influence of mortality on estimating the risk of kidney failure in people with stage 4 CKD. *J Am Soc Nephrol.* 2019;30(11):2219-2227.

29. Li L, Yang W, Astor BC, Greene T. Risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. *Clin J Am Soc Nephrol.* 2009;4(suppl_1):2284-2286.

30. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation.* 2016;133(6):601-609.

31. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2018 Annual Data Report: kidney. *Am J Transplant.* 2020;20(suppl 1):20-130.

32. Prommool S, Jiangi GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. *J Am Soc Nephrol.* 2000;11(3):565-573.

33. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *J Clin Epidemiol.* 2015;68(2):134-143.

34. Tangri N, Ferguson TW, Wiebe C, et al. Validation of the Kidney Failure Risk Equation in kidney transplant recipients. *Can J Kidney Health Dis.* 2020;7 https://doi.org/10.1177/2054358120922627.

35. Israni A, Dean C, Salkowski N, et al. Variation in structure and delivery of care between kidney transplant centers in the United States. *Transplantation.* 2014;98(5):520-528.

36. Grams ME, Coresh J, Segev DL, Kucirka LM, Tighiouart H, Sarnak MJ. Vascular disease, ESRD, and death: interpreting competing risk analyses. *Clin J Am Soc Nephrol.* 2012;7(10):1606-1614.

37. Winkelmaier WC, Kramar R, Curhan GC, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. *J Am Soc Nephrol.* 2005;16(1):255-260.

38. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG. Hyperhomocysteinemia in renal transplant recipients. *Am J Transplant.* 2002;2(4):308-313.

39. Dcool D, Motte G, Chaffier B, Gibey R, Chalopin J-M. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. *J Am Soc Nephrol.* 2000;11(1):134-137.
Can the Kidney Failure Risk Equation predict graft loss in kidney transplant recipients?

Validation study using data from FAVORIT trial
30 centers in US, Canada, Brazil

Adult kidney transplant recipients with functioning allografts
N=2,889

43% with living donor allograft
57% with deceased donor allograft

>6 months post-transplantation
Baseline eGFR <60 ml/min/1.73m²

Primary outcome
Graft loss

KFRE variables
Age
Gender
eGFR
UACR

Discrimination assessment (c-statistic) of KFRE

| Population | At 2 years (95% CI) | At 5 years (95% CI) |
|------------|---------------------|---------------------|
| Overall    | 0.85 (0.81-0.88)    | 0.81 (0.78-0.84)    |
| Graft vintage |            |                     |
| <2 years   | 0.83 (0.77-0.90)    | 0.78 (0.72-0.84)    |
| 2 to <5 years |   |                     |
| ≥5 years   | 0.85 (0.81-0.90)    | 0.82 (0.78-0.85)    |

Conclusion: The KFRE accurately predicts graft loss among adult kidney transplant recipients with graft vintage over 2 years and may be a useful prognostic tool in the care of kidney transplant recipients.

Reference: Chu CD et al. The Kidney Failure Risk Equation for prediction of allograft loss in kidney transplant recipients. Kidney Medicine, 2020

Visual abstract by Corina Teodosiu, MD.